CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Agendia NV is developing MammaPrint, a molecular diagnostic test for breast cancer recurrence that analyzes the entire human genome. This test aims to personalize treatment decisions, reducing the risk of over- or under-treatment for patients after surgery.
Agendia NV, a Dutch SME, was founded in 2003 as spin-off from the Netherlands Cancer Institute.
They pursue the commercialization of molecular diagnostics using DNA microarray technology for cancer.
Agendia aims to be one of the key market players in genomic breast cancer profiling.
One of the products Agendia is developing is MammaPrint, a breast cancer recurrence test.
This test identifies the risk of recurrence of cancer after surgical treatment, so that the appropriate adjuvant treatment can…
AGENDIA NV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
